Potentially Ototoxic Drugs Antibiotics Aminoglycosides - may produce cochleotoxicity Gentamicin Tobramycin Macrolides - produces reversible ototoxic effects in patients with kidney or liver damage Erythromycin Loop Diuretics - high doses can be ototoxic Furosemide Etharcrynic Bumetanide Chemotherapeutic agents - can cause high frequency hearing loss Platinum containing agents Cisplatin Carboplatin Oxaliplatin Heavy Metals Mercury Lead High Doses of Aspirin - can cause high pitched hearing loss References 1. Dobie RA, Black FO, Pezsnecker SC, Stallings VL (March 2006). "Hearing loss in patients with vestibulotoxic reactions to gentamicin therapy". Archives of Otolaryngology--Head & Neck Surgery 132 (3): 253–7. doi:10.1001/archotol. 132.3.253. PMID 16549744. http://archotol.ama-assn.org/cgi/pmidlookup? view=long&pmid=16549744. 2. Basile AS, Huang JM, Xie C, Webster D, Berlin C, Skolnick P (December 1996). "N-methyl-D-aspartate antagonists limit aminoglycoside antibiotic-induced hearing loss". Nature Medicine 2 (12): 1338–43. PMID 8946832. 3. Wu WJ, Sha SH, Schacht J (2002). "Recent advances in understanding aminoglycoside ototoxicity and its prevention". Audiology & Neuro-otology 7 (3): 171–4. PMID 12053140. http://content.karger.com/produktedb/produkte.asp? typ=fulltext&file=aud07171. 4. Munckhof WJ, Grayson ML, Turnidge JD (April 1996). "A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses". The Journal of Antimicrobial Chemotherapy 37 (4): 645–63. PMID 8722531. http://jac.oxfordjournals.org/cgi/pmidlookup? view=long&pmid=8722531. 5. Tepel M (August 2007). "N-Acetylcysteine in the prevention of ototoxicity". Kidney International 72 (3): 231–2. doi:10.1038/sj.ki.5002299. PMID 17653228. 6. Perez N, Martín E, García-Tapia R (March 2003). "Intratympanic gentamicin for intractable Ménière's disease". The Laryngoscope 113 (3): 456–64. doi:10.1097 /00005537-200303000-00013. PMID 12616197. 7. a b c d e f g h i j Roland, Peter S. (2004). Ototoxicity. Hamilton, Ont: B.C. Decker. ISBN 1-55009-263-4. 8. Voelker JR, Cartwright-Brown D, Anderson S, et al. (October 1987). "Comparison of loop diuretics in patients with chronic renal insufficiency". Kidney International 32 (4): 572–8. PMID 3430953. 9. a b Rademaker-Lakhai JM, Crul M, Zuur L, et al. (February 2006). "Relationship between cisplatin administration and the development of ototoxicity". Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 24 (6): 918–24. doi:10.1200/JCO.2006.10.077. PMID 16484702. http://www.jco. org/cgi/pmidlookup?view=long&pmid=16484702. 10. a b Hellberg V, Wallin I, Eriksson S, et al. (January 2009). "Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity". Journal of the National Cancer Institute 101 (1): 37–47. doi:10.1093 /jnci/djn418. PMID 19116379. PMC 2639295. http://jnci.oxfordjournals. org/cgi/pmidlookup?view=long&pmid=19116379. 11. Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V (April 2007). "Mechanisms of cisplatin-induced ototoxicity and prevention". Hearing Research 226 (1-2): 157–67. doi:10.1016/j.heares.2006.09.015. PMID 17113254. http: //linkinghub.elsevier.com/retrieve/pii/S0378-5955(06)00272-3. 12. Hensley ML, Hagerty KL, Kewalramani T, et al. (January 2009). "American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants". Journal of Clinical Oncology 27 (1): 127–45. doi:10.1200/JCO.2008.17.2627. PMID 19018081. http://www.jco. org/cgi/pmidlookup?view=long&pmid=19018081. |
| Canine Auditory Response Evaluation Mobile BAER Testing |



